Intraocular drug delivery systems

• US 8,969,415 B2
• Filed: 12/01/2006
• Issued: 03/03/2015
• Est. Priority Date: 12/01/2006
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Robinson, Michael R., Blanda, Wendy M., Hughes, Patrick M., Ruiz, Guadalupe, Orilla, Werhner C., Whitcup, Scott M., Welty, Devin F., Lin, Joan-En, Spada, Lon T.
• Primary Examiner(s): Huang, Gigi
• Application Number:
  US11/565,917
• Publication Number:
  US 20080131484A1
• Time in Patent Office: 3,014 Days
• Field of Search: 514/622, 514/913, 424/428
• US Class Current: 514/622
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/498 Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.

Claims

1. A method for treating glaucoma, the method comprising the step of placing multiple biodegradable rod shaped implants side-by-side into the anterior sub-Tenon'"'"'s region superotemporally 3 to 4 mm from the limbus in the eye, wherein each implant consists of

a) 15% by weight bimatoprost;

b) 75% by weight RG752S, which is a poly(D,L-lactide-co-glycolide) polymer having a D,L-lactide;

glycolide ratio of 75;

25 and having an inherent viscosity of between about 0.16 to 0.24 dl/g in 0.1% chloroform at 25°

C.; and

c) 10% by weight PEG 3350.

2. A biodegradable rod shaped implant for anterior sub-Tenon administration, with a length of about 2 mm or less and a width of 0.5 mm or less, consisting of:

a) 15% by weight bimatoprost;

b) 75% by weight RG752S, which is a poly(D,L-lactide-co-glycolide) polymer having a D,L-lactide;

glycolide ratio of 75;

25 and having an inherent viscosity of between about 0.16 to 0.24 dl/g in 0.1% chloroform at 25°

C.; and

c) 10% by weight PEG 3350.